Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 2/20 | 0.32 |
| ▸ | KLK7 | P49862 | 1/20 | 0.31 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405280 | 0.79 | CHRM2 (0.35) | NR1H2CHRM2CHRM1CHRM3MMP3 | |
| SCHEMBL24364276 | 0.79 | MEN1 (0.42) | NR1H2CHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL4774639 | 0.78 | MME (0.38) | NR1H2CHRM2CHRM1CHRM3MMP3 | |
| SCHEMBL29060412 | 0.77 | MMP3 (0.37) | NR1H2CHRM2CHRM1CHRM3MMP3 | |
| SCHEMBL433051 | 0.76 | CHRM2 (0.41) | NR1H2CHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL21452961 | 0.76 | CHRM2 (0.41) | NR1H2CHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL3744023 | 0.76 | CHRM2 (0.41) | NR1H2CHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL3738809 | 0.72 | CHRM2 (0.53) | NR1H2CHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL18878053 | 0.72 | CHRM2 (0.53) | NR1H2CHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL6442167 | 0.72 | CHRM2 (0.53) | NR1H2CHRM2CHRM1CHRM3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | NR1H2 408/4885CHRM2 13/4885CHRM1 7/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | NR1H2 408/4885CHRM2 13/4885CHRM1 7/4885 |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | NR1H2 408/4885CHRM2 13/4885CHRM1 7/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | NR1H2 408/4885CHRM2 13/4885CHRM1 7/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | NR1H2 408/4885CHRM2 13/4885CHRM1 7/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | NR1H2 408/4885CHRM2 13/4885CHRM1 7/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | NR1H2 408/4885CHRM2 13/4885CHRM1 7/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | NR1H2 76/4885CHRM2 158/4885CHRM1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.